Engineering Therapeutic Cancer Vaccines That Activate Antitumor Immunity
Vaccination represents one the most effective methods of preventing disease. Because dendritic cells (DCs) are the most efficient antigen presenting cells, exploiting their plasticity is likely to yield improved therapeutic vaccines. Herein, we applied a novel DC-based vaccine (i.e., DC loaded with leukemia antigens that have been transfected with an IL-10 siRNA capable of coordinately activating DCs via TLR7/8) in a rat model of acute myeloid leukemia. Leukemic rats treated with this new vaccine had less leukemic cell mass in their bone marrows and less extramedullar dissemination of the leukemic disease examined postmortem compared with rats given the control vaccine. Collectively, the new strategy demonstrates the possible usefulness of dual siRNAs as an immunomodulatory drug with antileukemic properties.
Key wordsDendritic cells siRNA Leukemia Immunotherapy
- 5.Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806–811Google Scholar
- 15.Martens AC, Johnson RJ, Kaizer H, Hagenbeek A (1984) Characteristics of a monoclonal antibody (RM124) against acute myelocytic leukemia cells. Exp Hematol 2:667–671Google Scholar